<<
>>
  • 特约嘉宾 Edit Title Edit Content Delete Content Hide Content
    Dr. Thomas G.
    Evans Managing Director, Novartis, China
    Dr.Ross J.
    Horsburgh,Vice President, Global Clinical Development Asia Pacific, Kendle International Inc
    Dr. Steven Lee
    CEO, A-Bio Pharma Pte Ltd, Singapore
    Dr.Dany Zhang
    Founder & Chief Medical Officer, VitalStrategic Research Institute, USA
    Ms. Liu YuWen
    General Manager, General Manager, SuZhuo BioBay China
    Dr.Ahmed Emara
    CEO & Managing Director, Jeddah BioCity Group, Kingdom Of Saudi Arabia
    Mr.Lei Ji Feng
    Founder & CEO, Shanghai Anbison Laboratories Co Ltd, China
    Dr. Jon Carrano
    General Manager & Regional Director, Phase Forward Pty Limited, Australia
    Mr. Andrew Qian
    Chairman, New Access Capital, China
    Dr.Yan Wu
    Medical & Clinical Development Director, Biogen Idec, China
    Dr Dan Weng
    Senior Vice President, Clinical Reearch Asia Pacific, PharmaNet ,USA
    Mr. Greg B. Scott
    President and Founder, ChinaBio? LLC
    • GB
    Matthew Chervenak
    Founder and CEO

    Mr Chervenak is founder and CEO of GB, Shanghai-based information, consulting, and advisory firm focused on China’s pharmaceutical and biotechnology industries. Since GB’s inception in 2002, Mr Chervenak has assisted clients in pharmaceuticals, biotechnology, private equity, and venture capital define and achieve their objectives in China. His key area of focus have been investment advisory, R&D strategy and execution, licensing, partner selection and market entry.
    Previously, Mr, Chervenak worked as a strategist for Sapient corporation in New York and conducted molecular biology research in government and academic instituitons. He holds a B,S. from the Pennsy lvania State University.



    辉瑞公司 亚洲（日本除外)
    Bradley Marchant, MD
    临床开发部总监

    Bradley joined Pfizer in 1995. In 1996, he became European Team Leader and subsequently Global Candidate Team Leader for Tikosyn, leading the development team to approvals in the US and EU. He subsequently held a series of leadership roles within clinical development including Site Clinical Leader for the Cardiovascular, Gastro-intestinal, Genito-urinary and Sexual Health Therapeutic Areas in Sandwich, UK. Bradley led the implementation of Enhanced Clinical Trial Design placing model based approaches at the heart of drug development. His current role is in Emerging Markets, Head of Clinical Development, Asia based in Shanghai.
    Prior to joining Pfizer, Bradley worked as a clinical cardiologist and maintains a specific interest in the QT interval as it relates to drug development. In 2005, Bradley was appointed Fellow of the Royal College of Physicians.



    诺和诺德（中国）制药有限公司
    Morten Stenkilde
    质量总监

    Work experience:
    Morten is member for the newly established Steering committee for ISPE Greater China. He has given speech to the Chinese FDA´s inspectors to support development of the pharmaceutical industry in China. Morten is hosting the COP for sterile manufacturing in China and is participating actively in developing and implementing strategies for ISPE Greater China.
    Performance:
    He has more than 15 years of pharmaceutical manufacturing experience in the areas of solid dosage, contract manufacturing and sterile manufacturing. Morten has been part of construction projects for both solid dosage and sterile manufacturing. Morten has international project experience from Denmark, Brazil and recently China. He has experience from production departments, Quality departments, logistic departments as well as project management in the pharmaceutical industry.
    He has been assigned to the construction of Novo Nordisk A/S facilities for insulin filling in China. Morten is responsible for a proactive Quality organization to ensure fast delivery and release to the world wide market. This includes close corporations authorities in China.



    ChinaBio公司
    Greg B. Scott
    主席

    Education background:
    Mr. Scott attended University of Missouri, where he studied mathematics, microbiology and computer science.
    Work experience:
    Mr. Scott has helped launch over thirty life science startups in the U.S. and China as a founder, investor and advisor. He founded the ChinaBio® LLC in January 2007 to help fund and mentor early stage life science companies in China, and provide consulting and research services to pharma and biotech companies with business interests in China. Mr. Scott is also the president and co-founder of Life Science Angels, an angel investment group that has funded 30 biotechnology and medical device companies since 2005, and executive editor of ChinaBio® Today.  He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and was co-founder of a 200-person consulting firm



    美冠科生物技术（北京）有限公司
    Dr. Jean-Pierre Wery
    总裁

    Dr. Wery is currently President of Crown Bioscience, inc. Prior to joining Crown, Dr. Wery was Chief Scientific Officer at Monarch Life Sciences, a company dedicated to the discovery and development of protein biomarkers. Prior to joining Monarch, Dr. Wery spent three years at Vitae Pharmaceuticals, Inc. where he was VP of Drug Discovery. Before joining Vitae he worked for 12 years at Eli Lilly and Company in various scientific and management positions. Dr. Wery received his B.S. and Ph.D. in Physics from the U. of Liege, Belgium. Following his Ph.D., he did postdoctoral studies at Purdue University with Prof. Jack Johnson. Dr. Wery has authored more than 50 abstracts and publications